<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015457</url>
  </required_header>
  <id_info>
    <org_study_id>010147</org_study_id>
    <secondary_id>01-N-0147</secondary_id>
    <nct_id>NCT00015457</nct_id>
  </id_info>
  <brief_title>Amlodipine Plus Botulinum Toxin for Focal Dystonia</brief_title>
  <official_title>Trial of Amlodipine Combined With Botulinum Toxin Injections for Focal Dystonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Objective: To determine if the calcium channel blockers, amlodipine can augment the effect of
      botulinum toxin injections in the treatment of focal dystonia.

      Study Population: 20 patients with cervical dystonia

      Design: Double-bind, placebo-controlled clinical trail.

      Outcome measures: For patients: dystonia rating scales (Twistrs, Fahn-Marsden dystonia scale,
      NINDS subjective patient rating scale), and hand grip strength. For healthy volunteers:
      Amplitude of EDB MEP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To determine if the calcium channel blocker, amlodipine can augment the effect of
      botulinum toxin injections in the treatment of focal dystonia.

      Study Population: 20 patients with cervical dystonia

      Design: Double-bind, placebo-controlled clinical trail.

      Outcome measures: dystonia rating scales (TWISTRS)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score</measure>
    <time_frame>1-2 month maximal rating</time_frame>
    <description>Rating scale assessing sum of severity of dystonia, disability score and pain scale. Ordinal scale ranging from 0 (least severe) to 30 (maximally severe). Score is maximal response TWSTR rating minus baseline rating.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response to Botulinum Toxin Injection With Amlodipine and With Placebo</measure>
    <time_frame>3 months</time_frame>
    <description>Self reported duration of effect in weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Focal Dystonia</condition>
  <arm_group>
    <arm_group_label>cervical dystonia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cervical dsytonia patinets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine plus Botulinum toxin</intervention_name>
    <arm_group_label>cervical dystonia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Patients enrolled in Protocol 85-N-0195, Efficacy and Pathophysiology of Botulinum Toxin
        for Treatment of Involuntary Movement Disorders are eligible for enrollment if they meet
        the following inclusion and exclusion criteria.

        Good general health

        Focal hand dystonia or cervical dystonia

        Stable response to botulinum toxin demonstrated through a series of at least 3 injections
        over a period of at least a year

        Benefit from the 3 immediately prior btx injections rated as 75% or less or a duration of
        benefit lasting less than or equal to 2 months

        No other medications for dystonia

        EXCLUSION CRITERIA:

        Cervical dystonia accompanied by dysphagia or dyspnea, either before or with botulinum
        toxin injection

        Present or past cardiac disease, hypertension, arrhythmia or congestive heart failure

        Anterocollis or other neck dystonia requiring bilateral anterior neck muscle injections

        Use of concomitant medications affecting calcium channels or those metabolized by the
        cytochrome p450 3A4 system including grapefruit juice, St. John's wort, HIV protease
        inhibitors, cimetidine, antibiotics (macrolides, fluoroquinones, antifungal, rifampin),
        antidepressants (fluvoxamine, norfluoxetine), barbiturates, anticonvulsants (carbamazepine,
        phenytoin), oral diabetes agents (pioglitazone, troglitazone), and glucocorticoids

        Allergy to amlodipine or related compounds

        Pregnany/ nursing

        Age less than 18 years of age

        Abnormal EKG

        Abnormal coagulation profile or liver function tests

        Use of anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthalmic Plast Reconstr Surg. 1998 Sep;14(5):305-17.</citation>
    <PMID>9783280</PMID>
  </reference>
  <reference>
    <citation>Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology. 1990 Feb;40(2):277-80.</citation>
    <PMID>2300249</PMID>
  </reference>
  <reference>
    <citation>Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug;53(8):633-9.</citation>
    <PMID>2213039</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2001</study_first_submitted>
  <study_first_submitted_qc>April 18, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2001</study_first_posted>
  <results_first_submitted>March 14, 2013</results_first_submitted>
  <results_first_submitted_qc>March 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2013</results_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Barbara Karp, M.D.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Writer's Cramp</keyword>
  <keyword>Calcium Channel Antagonists</keyword>
  <keyword>Torticollis</keyword>
  <keyword>Chemodenervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from a medical clinic providing botulinum toxin treatment for cervical dystonia. Patients recruited between 6/21/01 and 10/19/06</recruitment_details>
      <pre_assignment_details>Patients were excluded if response to previous btx injections were not stable, serious medical conditions, pregnancy, abnormal medical screening</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine Then Placebo</title>
          <description>Patients with cervical dystonia receiving botulinum toxin injections plus Amlodipine during the first period and botulinum toxin injections plus Placebo during the second period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Amlodipine</title>
          <description>Patients with cervical dystonia receiving botulinum toxin injections plus Placebo during the first period and botulinum toxin injections plus Amlodipine during the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervical Dystonia</title>
          <description>All participants enrolled in study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>age &gt;18</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score</title>
        <description>Rating scale assessing sum of severity of dystonia, disability score and pain scale. Ordinal scale ranging from 0 (least severe) to 30 (maximally severe). Score is maximal response TWSTR rating minus baseline rating.</description>
        <time_frame>1-2 month maximal rating</time_frame>
        <population>Total enrolled less withdrawals from study. One participant completed the study but did not yield analyzeable data</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Patients receiving Amlodipine plus botulinum toxin injections during either period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receiving Placebo plus botulinum toxin injections during either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score</title>
          <description>Rating scale assessing sum of severity of dystonia, disability score and pain scale. Ordinal scale ranging from 0 (least severe) to 30 (maximally severe). Score is maximal response TWSTR rating minus baseline rating.</description>
          <population>Total enrolled less withdrawals from study. One participant completed the study but did not yield analyzeable data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.00" spread="10.23"/>
                    <measurement group_id="O2" value="-3.23" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response to Botulinum Toxin Injection With Amlodipine and With Placebo</title>
        <description>Self reported duration of effect in weeks.</description>
        <time_frame>3 months</time_frame>
        <population>Total enrolled less withdrawals. Less one participant who completed the study but who did not yield analyzeable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine</title>
            <description>Patients receiving Amlodipine plus botulinum toxin injections during either period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receiving Placebo plus botulinum toxin injections during either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response to Botulinum Toxin Injection With Amlodipine and With Placebo</title>
          <description>Self reported duration of effect in weeks.</description>
          <population>Total enrolled less withdrawals. Less one participant who completed the study but who did not yield analyzeable data.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="5.5" lower_limit="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amlodipine</title>
          <description>Patients receiving Amlodipine plus botulinum toxin injections during either period.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients receiving Placebo plus botulinum toxin injections during either period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hypereosinophila</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>swelling</sub_title>
                <description>ankle edema</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara I Karp, MD</name_or_title>
      <organization>National Institutes of Health</organization>
      <phone>301-496-0150</phone>
      <email>karpb@ninds.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

